Recent insights into the pathogenesis of hepatic encephalopathy and treatments

Expert Review of Gastroenterology and Hepatology

Volumn 8, Issue 1, 2014, Pages 83-100

  Sturgeon, Jonathan P ^a   Shawcross, Debbie L ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

acute liver failure; ammonia; astrocyte; cerebral edema; cirrhosis; hepatic encephalopathy; inflammation; treatments

Indexed keywords

4 PHENYLBUTYRIC ACID; ACETYLCYSTEINE; ALBUMIN; AMMONIA; AST 120; BENZOIC ACID; BICUCULLINE; BRANCHED CHAIN AMINO ACID; CARNITINE; DISACCHARIDE; FLUMAZENIL; INDOMETACIN; LACTITOL; LACTULOSE; MANNITOL; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; ORNITHINE ASPARTATE; ORNITHINE PHENYLACETATE; PHENYLACETIC ACID; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROBIOTIC AGENT; RIFAXIMIN; SILDENAFIL; ZAPRINAST;

ACUTE LIVER FAILURE; BRAIN EDEMA; CELL SWELLING; CHRONIC LIVER FAILURE; DRUG ABSORPTION; DRUG EXCRETION; DRUG TARGETING; ENDOTOXEMIA; GABAERGIC SYSTEM; HEPATIC ENCEPHALOPATHY; HORMONE SUBSTITUTION; HUMAN; HYPERAMMONEMIA; INDUCED HYPOTHERMIA; INNATE IMMUNITY; LIVER TOXICITY; LIVER TRANSPLANTATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PLASMAPHERESIS; PROTEIN RESTRICTION; REVIEW;

AMMONIA; ANTI-BACTERIAL AGENTS; HEMOFILTRATION; HEPATIC ENCEPHALOPATHY; HUMANS; HYPOTHERMIA, INDUCED; OXIDATIVE STRESS; SYNAPTIC TRANSMISSION;

EID: 84893046992     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2014.858598     Document Type: Review

References (184)

1. Bajaj JS, Wade JB, Sanyal AJ. Spectrum of neurocognitive impairment in cirrhosis: Implications for the assessment of hepatic encephalopathy. Hepatology 50(6), 2014-2021 (2009
2. Ferenci P, Lockwood A, Mullen K, Tarter R, Weissenborn K, Blei AT. Hepatic encephalopathy-definition, nomenclature, diagnosis, and quantification: Final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998. Hepatology 35(3), 716-721 (2002
3. Cauli O, Rodrigo R, Llansola M et al. Glutamatergic and gabaergic neurotransmission and neuronal circuits in hepatic encephalopathy. Metab. Brain Dis. 24(1), 69-80 (2009
4. Riordan SM, Williams R. Treatment of hepatic encephalopathy. N. Engl. J. Med. 337(7), 473-479 (1997
5. Bernal W, Hyyrylainen A, Gera A et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J. Hepatol. 59(1), 74-80 (2013
6. Dhiman RK, Kurmi R, Thumburu KK et al. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig. Dis. Sci. 55(8), 2381-2390 (2010
7. Das A, Dhiman RK, Saraswat VA, Verma M, Naik SR. Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis. J. Gastroenterol Hepatol. 16(5), 531-535 (2001
8. Alqahtani SA, Larson AM. Adult liver transplantation in the USA. Curr. Opin. Gastroenterol. 27(3), 240-247 (2011
9. Amodio P, Del Piccolo F, Petteno E et al. Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients. J. Hepatol. 35(1), 37-45 (2001
10. Quero JC, Schalm SW. Subclinical hepatic encephalopathy. Semin. Liver Dis. 16(3), 321-328 (1996
11. Kircheis G, Knoche A, Hilger N et al. Hepatic encephalopathy and fitness to drive. Gastroenterology 137(5), 1706-1715, e1701-1709 (2009
12. Bajaj JS, Saeian K, Schubert CM et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: The reality beyond the driving test. Hepatology 50(4), 1175-1183 (2009
13. Dhiman RK, Chawla YK. Minimal hepatic encephalopathy. Indian J. Gastroenterol. 28(1), 5-16 (2009
14. Butterworth RF. Pathophysiology of hepatic encephalopathy: A new look at ammonia. Metab. Brain Dis. 17(4), 221-227 (2002
15. Olde Damink SW, Deutz NE, Dejong CH, Soeters PB, Jalan R. Interorgan ammonia metabolism in liver failure. Neurochem. Int. 41(2-3), 177-188 (2002
16. Shawcross DL, Davies NA, Williams R, Jalan R. Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J. Hepatol. 40(2), 247-254 (2004
17. Tranah TH, Vijay GK, Ryan JM, Shawcross DL. Systemic inflammation and ammonia in hepatic encephalopathy. Metab. Brain Dis. 28(1), 1-5 (2013
18. Coltart I, Tranah TH, Shawcross DL. Inflammation and hepatic encephalopathy. Arch. Biochem. Biophys. 536(2), 189-196 (2013
19. Wright G, Davies NA, Shawcross DL et al. Endotoxemia produces coma and brain swelling in bile duct ligated rats. Hepatology 45(6), 1517-1526 (2007
20. Rose CF. Ammonia-lowering strategies for the treatment of hepatic encephalopathy. Clin. Pharmacol. Ther. 92(3), 321-331 (2012
21. Romero-Gómez M, Ramos-Guerrero R, Grande L et al. Intestinal glutaminase activity is increased in liver cirrhosis and correlates with minimal hepatic encephalopathy. J. Hepatol. 41(1), 49-54 (2004
22. Haussinger D, Lamers WH, Moorman AF. Hepatocyte heterogeneity in the metabolism of amino acids and ammonia. Enzyme 46 (1-3), 72-93 (1992
23. Anand U, Anand CV. Teaching the urea cycle: The role of liver in acid-base regulation. Biochem. Educ. 25(1), 20-21 (1997
24. Wright G, Noiret L, Olde Damink SW, Jalan R. Interorgan ammonia metabolism in liver failure: The basis of current and future therapies. Liver Int. 31(2), 163-175 (2011
25. Romero-Gomez M, Jover M, Galan JJ, Ruiz A. Gut ammonia production and its modulation. Metab. Brain Dis. 24(1), 147-157 (2009
26. Dejong CH, Deutz NE, Soeters PB. Metabolic adaptation of the kidney to hyperammonemia during chronic liver insufficiency in the rat. Hepatology 18(4), 890-902 (1993
27. Olde Damink SW, Jalan R, Dejong CH. Interorgan ammonia trafficking in liver disease. Metab. Brain Dis. 24(1), 169-181 (2009
28. Mpabanzi L, van den Broek MA, Visschers RG et al. Urinary ammonia excretion increases acutely during living donor liver transplantation. Liver Int. 31(8), 1150-1154 (2011
29. Olde Damink SW, Jalan R, Deutz NE et al. The kidney plays a major role in the hyperammonemia seen after simulated or actual GI bleeding in patients with cirrhosis. Hepatology 37(6), 1277-1285 (2003
30. Rao KV, Panickar KS, Jayakumar AR, Norenberg MD. Astrocytes protect neurons from ammonia toxicity. Neurochem. Res. 30(10), 1311-1318 (2005
31. Moser H. Electrophysiological evidence for ammonium as a substitute for potassium in activating the sodium pump in a crayfish sensory neuron. Can. J. Physiol. Pharmacol. 65(2), 141-145 (1987
32. Bakouh N, Benjelloun F, Cherif-Zahar B, Planelles G. The challenge of understanding ammonium homeostasis and the role of the Rh glycoproteins. Transfus. Clin. Biol. 13(1-2), 139-146 (2006
33. Keiding S, Sorensen M, Bender D, Munk OL, Ott P, Vilstrup H. Brain metabolism of 13N-Ammonia during acute hepatic encephalopathy in cirrhosis measured by positron emission tomography. Hepatology 43(1), 42-50 (2006
34. Balata S, Olde Damink SW, Ferguson K et al. Induced hyperammonemia alters neuropsychology, brain MR spectroscopy and magnetization transfer in cirrhosis. Hepatology 37(4), 931-939 (2003
35. Fernandes SP, Dringen R, Lawen A, Robinson SR. Neurones express glutamine synthetase when deprived of glutamine or interaction with astrocytes. J. Neurochem. 114(5), 1527-1536 (2010
36. Shawcross DL, Wendon JA. The neurological manifestations of acute liver failure. Neurochem. Int. 60(7), 662-671 (2012
37. Clemmesen JO, Larsen FS, Kondrup J, Hansen BA, Ott P. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29(3), 648-653 (1999
38. Bernal W, Hall C, Karvellas CJ, Auzinger G, Sizer E, Wendon J. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology 46(6), 1844-1852 (2007
39. Cordoba J, Alonso J, Rovira A et al. The development of low-grade cerebral edema in cirrhosis is supported by the evolution of (1)H-magnetic resonance abnormalities after liver transplantation. J. Hepatol. 35(5), 598-604 (2001
40. Cauli O, Llansola M, Agusti A et al. Cerebral oedema is not responsible for motor or cognitive deficits in rats with hepatic encephalopathy. Liver Int. doi:10.1111/liv.12258 (2013) (Epub ahead of print
41. Joshi D, O'apos;Grady J, Patel A et al. Cerebral oedema is rare in acute-on-chronic liver failure patients presenting with high-grade hepatic encephalopathy. Liver Int. doi:10.1111/liv.12257 (2013) (Epub ahead of print
42. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 51(3), 1062-1069 (2010
43. Fan P, Szerb JC. Effects of ammonium ions on synaptic transmission and on responses to quisqualate and N-methyl-D-Aspartate in hippocampal CA1 pyramidal neurons in vitro. Brain Res. 632(1-2), 225-231 (1993
44. Bosoi CR, Rose CF. Identifying the direct effects of ammonia on the brain. Metab. Brain Dis. 24(1), 95-102 (2009
45. Hermenegildo C, Monfort P, Felipo V. Activation of N-methyl-D-Aspartate receptors in rat brain in vivo following acute ammonia intoxication: Characterization by in vivo brain microdialysis. Hepatology 31(3), 709-715 (2000
46. Llansola M, Rodrigo R, Monfort P et al. NMDA receptors in hyperammonemia and hepatic encephalopathy. Metab. Brain Dis. 22(3-4), 321-335 (2007
47. Minana MD, Felipo V, Grisolia S. Protective effect of long term ammonium ingestion against acute ammonium intoxication. Biochem. Biophys. Res. Commun. 153(3), 979-983 (1988
48. Kosenko E, Felipo V, Minana MD, Grau E, Grisolia S. Ammonium ingestion prevents depletion of hepatic energy metabolites induced by acute ammonium intoxication. Arch. Biochem. Biophys. 290(2), 484-488 (1991
49. Kosenko E, Kaminsky YG, Felipo V, Minana MD, Grisolia S. Chronic hyperammonemia prevents changes in brain energy and ammonia metabolites induced by acute ammonium intoxication. Biochim. Biophys. Acta 1180(3), 321-326 (1993
50. Hermenegildo C, Montoliu C, Llansola M et al. Chronic hyperammonemia impairs the glutamate-nitric oxide-cyclic GMP pathway in cerebellar neurons in culture and in the rat in vivo. Eur. J. Neurosci. 10(10), 3201-3209 (1998
51. Corbalan R, Chatauret N, Behrends S, Butterworth RF, Felipo V. Region selective alterations of soluble guanylate cyclase content and modulation in brain of cirrhotic patients. Hepatology 36(5), 1155-1162 (2002
52. Erceg S, Monfort P, Cauli O et al. Role of extracellular cGMP and of hyperammonemia in the impairment of learning in rats with chronic hepatic failure. Therapeutic implications. Neurochem. Int. 48(6-7), 441-446 (2006
53. Erceg S, Monfort P, Hernandez-Viadel M, Llansola M, Montoliu C, Felipo V. Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain. Brain Res. 1036(1-2), 115-121 (2005
54. Erceg S, Monfort P, Hernandez-Viadel M, Rodrigo R, Montoliu C, Felipo V. Oral administration of sildenafil restores learning ability in rats with hyperammonemia and with portacaval shunts. Hepatology 41(2), 299-306 (2005
55. Schafer DF, Jones EA. Hepatic encephalopathy and the g-Aminobutyric-Acid neurotransmitter system. Lancet 1(8262), 18-20 (1982
56. Ahboucha S, Butterworth RF. Pathophysiology of hepatic encephalopathy: A new look at GABA from the molecular standpoint. Metab. Brain Dis. 19(3-4), 331-343 (2004
57. Jones EA. Potential mechanisms of enhanced GABA-mediated inhibitory neurotransmission in liver failure. Neurochem. Int. 43(4-5), 509-516 (2003
58. Lavoie J, Layrargues GP, Butterworth RF. Increased densities of peripheral-Type benzodiazepine receptors in brain autopsy samples from cirrhotic patients with hepatic encephalopathy. Hepatology 11(5), 874-878 (1990
59. Ahboucha S, Pomier-Layrargues G, Mamer O, Butterworth RF. Increased levels of pregnenolone and its neuroactive metabolite allopregnanolone in autopsied brain tissue from cirrhotic patients who died in hepatic coma. Neurochem. Int. 49(4), 372-378 (2006
60. Jalan R, Turjanski N, Taylor-Robinson SD et al. Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis. Gut 46(4), 546-552 (2000
61. Cauli O, Mansouri MT, Agusti A, Felipo V. Hyperammonemia Increases GABAergic Tone in the Cerebellum but Decreases It in the Rat Cortex. Gastroenterology 136(4), 1359-1367, e1352 (2009
62. Bjerring PN, Eefsen M, Hansen BA, Larsen FS. The brain in acute liver failure. A tortuous path from hyperammonemia to cerebral edema. Metab. Brain Dis. 24(1), 5-14 (2009
63. Zwingmann C, Chatauret N, Leibfritz D, Butterworth RF. Selective increase of brain lactate synthesis in experimental acute liver failure: Results of a [1H-13C] nuclear magnetic resonance study. Hepatology 37(2), 420-428 (2003
64. Kosenko E, Kaminsky Y, Grau E et al. Brain ATP depletion induced by acute ammonia intoxication in rats is mediated by activation of the NMDA receptor and Na+, K(+)-ATPase. J. Neurochem. 63(6), 2172-2178 (1994
65. Albrecht J, Norenberg MD. Glutamine: A Trojan horse in ammonia neurotoxicity. Hepatology 44(4), 788-794 (2006
66. Sonnewald U, Westergaard N, Jones P, Taylor A, Bachelard HS, Schousboe A. Metabolism of [U-13C5] glutamine in cultured astrocytes studied by NMR spectroscopy: First evidence of astrocytic pyruvate recycling. J. Neurochem. 67(6), 2566-2572 (1996
67. Bai G, Rama Rao KV, Murthy CR, Panickar KS, Jayakumar AR, Norenberg MD. Ammonia induces the mitochondrial permeability transition in primary cultures of rat astrocytes. J. Neurosci. Res. 66(5), 981-991 (2001
68. Zoratti M, Szabo I, De Marchi U. Mitochondrial permeability transitions: How many doors to the house? Biochim. Biophys. Acta 1706(1-2), 40-52 (2005
69. Rama Rao KV, Jayakumar AR, Norenberg MD. Role of oxidative stress in the ammonia-induced mitochondrial permeability transition in cultured astrocytes. Neurochem. Int. 47(1-2), 31-38 (2005
70. Shawcross DL, Sharifi Y, Canavan JB et al. Infection and systemic inflammation, not ammonia, are associated with Grade 3/ 4 hepatic encephalopathy, but not mortality in cirrhosis. J. Hepatol. 54(4), 640-649 (2011
71. Ong JP, Aggarwal A, Krieger D et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am. J. Med. 114(3), 188-193 (2003
72. Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J. Hepatol. 38(4), 441-446 (2003
73. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin. Liver Dis. 16(4), 389-402 (1996
74. Rolando N, Wade J, Davalos M, Wendon J, Philpott-Howard J, Williams R. The systemic inflammatory response syndrome in acute liver failure. Hepatology 32(4 Pt 1), 734-739 (2000
75. Vaquero J, Polson J, Chung C et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology 125(3), 755-764 (2003
76. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 127(5), 1338-1346 (2004
77. Jalan R, Pollok A, Shah SH, Madhavan K, Simpson KJ. Liver derived pro-inflammatory cytokines may be important in producing intracranial hypertension in acute liver failure. J. Hepatol. 37(4), 536-538 (2002
78. Shawcross DL, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. Metab. Brain Dis. 22(1), 125-138 (2007
79. Marini JC, Broussard SR. Hyperammonemia increases sensitivity to LPS. Mol. Genet. Metab. 88(2), 131-137 (2006
80. Felipo V, Urios A, Montesinos E et al. Contribution of hyperammonemia and inflammatory factors to cognitive impairment in minimal hepatic encephalopathy. Metab. Brain Dis. 27(1), 51-58 (2012
81. Vorobioff J, Bredfeldt JE, Groszmann RJ. Hyperdynamic circulation in portal-hypertensive rat model: A primary factor for maintenance of chronic portal hypertension. Am. J. Physiol. 244(1), G52-57 (1983
82. Cirera I, Bauer TM, Navasa M et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J. Hepatol. 34(1), 32-37 (2001
83. Llovet JM, Bartoli R, March F et al. Translocated intestinal bacteria cause spontaneous bacterial peritonitis in cirrhotic rats: Molecular epidemiologic evidence. J. Hepatol. 28(2), 307-313 (1998
84. Perez del Pulgar S, Pizcueta P, Engel P, Bosch J. Enhanced monocyte activation and hepatotoxicity in response to endotoxin in portal hypertension. J. Hepatol. 32(1), 25-31 (2000
85. Bigatello LM, Broitman SA, Fattori L et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am. J. Gastroenterol. 82(1), 11-15 (1987
86. Montoliu C, Piedrafita B, Serra MA et al. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. J. Clin. Gastroenterol. 43(3), 272-279 (2009
87. Panasiuk A, Wysocka J, Maciorkowska E et al. Phagocytic and oxidative burst activity of neutrophils in the end stage of liver cirrhosis. World J. Gastroenterol. 11(48), 7661-7665 (2005
88. Bonnel AR, Bunchorntavakul C, Reddy KR. Immune dysfunction and infections in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 9(9), 727-738 (2011
89. Mookerjee RP, Stadlbauer V, Lidder S et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 46(3), 831-840 (2007
90. Shawcross DL, Wright GA, Stadlbauer V et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 48(4), 1202-1212 (2008
91. Taylor NJ, Nishtala A, Manakkat Vijay GK et al. Circulating neutrophil dysfunction in acute liver failure. Hepatology 57(3), 1142-1152 (2013
92. Stadlbauer V, Mookerjee RP, Hodges S, Wright GA, Davies NA, Jalan R. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J. Hepatol. 48(6), 945-951 (2008
93. Vijay GKM, Abeles RD, Ramage S et al. PMO-125 Neutrophil intracellular toll-like receptor (TLR) 9 expression serves as a biomarker that determines presence and severity of encephalopathy in acute liver failure and cirrhosis. Gut 61(Suppl. 2), A123-A124 (2012
94. Borzio M, Salerno F, Piantoni L et al. Bacterial infection in patients with advanced cirrhosis: A multicentre prospective study. Dig. Liver Dis. 33(1), 41-48 (2001
95. Cauli O, Rodrigo R, Piedrafita B, Boix J, Felipo V. Inflammation and hepatic encephalopathy: Ibuprofen restores learning ability in rats with portacaval shunts. Hepatology 46(2), 514-519 (2007
96. Rodrigo R, Cauli O, Gomez-Pinedo U et al. Hyperammonemia induces neuroinflammation that contributes to cognitive impairment in rats with hepatic encephalopathy. Gastroenterology 139(2), 675-684 (2010
97. Jiang W, Desjardins P, Butterworth RF. Direct evidence for central proinflammatory mechanisms in rats with experimental acute liver failure: Protective effect of hypothermia. J. Cereb. Blood Flow Metab. 29(5), 944-952 (2009
98. Jiang W, Desjardins P, Butterworth RF. Cerebral inflammation contributes to encephalopathy and brain edema in acute liver failure: Protective effect of minocycline. J. Neurochem. 109(2), 485-493 (2009
99. Rangroo Thrane V, Thrane AS, Chang J, Alleluia V, Nagelhus EA, Nedergaard M. Real-Time analysis of microglial activation and motility in hepatic and hyperammonemic encephalopathy. Neuroscience 220, 247-255 (2012
100. Butterworth RF. The liver-brain axis in liver failure: Neuroinflammation and encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 10(9), 522-528 (2013
101. Sharma BC, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: An open-label randomized controlled trial of lactulose versus placebo. Gastroenterology 137(3), 885-891, 891 e891 (2009
102. Alba L, Hay JE, Angulo P, Lee WM. Lactulose therapy in acute liver failure. J. Hepatol. 36, 33 (2002
103. Polson J, Lee WM. AASLD position paper: The management of acute liver failure. Hepatology 41(5), 1179-1197 (2005
104. Als-Nielsen B, Gluud LL, Gluud C. Non-Absorbable disaccharides for hepatic encephalopathy: Systematic review of randomised trials. BMJ 328(7447), 1046 (2004
105. Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology 45(3), 549-559 (2007
106. Gluud LL, Dam G, Borre M et al. Lactulose, rifaximin or branched chain amino acids for hepatic encephalopathy: What is the evidence? Metab. Brain Dis. 28(2), 221-225 (2013
107. Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. N. Engl. J. Med. 362(12), 1140-1142 (2010
108. DuPont HL. Biologic properties and clinical uses of rifaximin. Expert Opin. Pharmacother. 12(2), 293-302 (2011
109. Bucci L, Palmieri GC. Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr. Med. Res. Opin. 13(2), 109-118 (1993
110. Loguercio C, Federico A, De Girolamo V, Ferrieri A, Del Vecchio Blanco C. Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol. Dietol. 49(1), 53-62 (2003
111. Sharma BC, Sharma P, Lunia MK, Srivastava S, Goyal R, Sarin SK. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am. J. Gastroenterol. 108(9), 1458-1463 (2013
112. Festi D, Mazzella G, Orsini M et al. Rifaximin in the treatment of chronic hepatic-encephalopathy-results of a multicenter study of efficacy and safety. Curr. Ther. Res. Clin. E 54(5), 598-609 (1993
113. Paik YH, Lee KS, Han KH et al. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: A prospective randomized study. Yonsei Med. J. 46(3), 399-407 (2005
114. Mas A, Rodes J, Sunyer L et al. Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J. Hepatol. 38(1), 51-58 (2003
115. Jiang Q, Jiang XH, Zheng MH, Jiang LM, Chen YP, Wang L. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: A meta-Analysis. Eur. J. Gastroenterol. Hepatol. 20(11), 1064-1070 (2008
116. Bass NM, Mullen KD, Sanyal A et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362(12), 1071-1081 (2010
117. Kalambokis GN, Tsianos EV. Rifaximin reduces endotoxemia and improves liver function and disease severity in patients with decompensated cirrhosis. Hepatology 55(2), 655-656 (2012
118. Rose C, Michalak A, Pannunzio P et al. L-ornithine-L-Aspartate in experimental portal-systemic encephalopathy: Therapeutic efficacy and mechanism of action. Metab. Brain Dis. 13(2), 147-157 (1998
119. Gebhardt R, Beckers G, Gaunitz F et al. Treatment of cirrhotic rats with L-ornithine-L-Aspartate enhances urea synthesis and lowers serum ammonia levels. J. Pharmacol. Exp. Ther. 283(1), 1-6 (1997
120. Soarez PC, Oliveira AC, Padovan J, Parise ER, Ferraz MB. A critical analysis of studies assessing L-ornithine-L-Aspartate (LOLA) in hepatic encephalopathy treatment. Arq. Gastroenterol. 46(3), 241-247 (2009
121. Mittal VV, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-Aspartate in treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 23(8), 725-732 (2011
122. Poo JL, Gongora J, Sanchez-Avila F et al. Efficacy of oral L-ornithine-L-Aspartate in cirrhotic patients with hyperammonemic hepatic encephalopathy. Results of a randomized, lactulose-controlled study. Ann. Hepatol. 5(4), 281-288 (2006
123. Acharya SK, Bhatia V, Sreenivas V, Khanal S, Panda SK. Efficacy of L-ornithine L-Aspartate in acute liver failure: A double-blind, randomized, placebo-controlled study. Gastroenterology 136(7), 2159-2168 (2009
124. Leonard JV, Morris AA. Urea cycle disorders. Semin. Neonatol. 7(1), 27-35 (2002
125. Slack AJ, Auzinger G, Willars C et al. Ammonia clearance with haemofiltration in adults with liver disease. Liver Int. doi:10.1111/liv.12221 (2013) (Epub ahead of print
126. Stravitz RT, Larsen FS. Therapeutic hypothermia for acute liver failure. Crit. Care Med. 37(7 Suppl.), S258-S264 (2009
127. Jalan R, O'Damink SW, Deutz NE, Lee A, Hayes PC. Moderate hypothermia for uncontrolled intracranial hypertension in acute liver failure. Lancet 354(9185), 1164-1168 (1999
128. Jalan R, Olde Damink SW, Deutz NE et al. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation 75(12), 2034-2039 (2003
129. Jalan R, Olde Damink SW, Deutz NE, Hayes PC, Lee A. Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia. Hepatology 34(1), 50-54 (2001
130. Larsen FS, Murphy N, Bernal W, Bjerring PN, Hauerberg J, Wendon J. 56 the prophylactive effect of mild hypothermia to prevent brain edema in patients with acute liver failure: Results of a multicenter randomized, controlled trial. J. Hepatol. 54, S26 (2011
131. Lee WM, Hynan LS, Rossaro L et al. Intravenous N-Acetylcysteine improves transplant-free survival in early stage non-Acetaminophen acute liver failure. Gastroenterology 137(3), 856-864, 864, e851 (2009
132. Bémeur C, Vaquero J, Desjardins P, Butterworth R. N-Acetylcysteine attenuates cerebral complications of non-Acetaminophen-induced acute liver failure in mice: Antioxidant and anti-inflammatory mechanisms. Metab. Brain Dis. 25(2), 241-249 (2010
133. Lee WM, Stravitz RT, Larson AM Introduction to the revised American Association for the study of liver diseases position paper on acute liver failure 2011. Hepatology 55(3), 965-967 (2012
134. Sherlock S, Summerskill WH, White LP, Phear EA. Portal-systemic encephalopathy; neurological complications of liver disease. Lancet 267(6836), 454-457 (1954
135. Amodio P, Bemeur C, Butterworth R et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: International Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology 58(1), 325-336 (2013
136. Cordoba J, Lopez-Hellin J, Planas M et al. Normal protein diet for episodic hepatic encephalopathy: Results of a randomized study. J. Hepatol. 41(1), 38-43 (2004
137. Plauth M, Merli M, Kondrup J et al. ESPEN guidelines for nutrition in liver disease and transplantation. Clin. Nutr. 16(2), 43-55 (1997
138. Rana S, Sodhi CP, Mehta S et al. Protein-energy malnutrition and oxidative injury in growing rats. Hum. Exp. Toxicol. 15(10), 810-814 (1996
139. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: Effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 39(5), 1441-1449 (2004
140. Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled study. Dig. Dis. Sci. 52(11), 3259-3265 (2007
141. Sharma P, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur. J. Gastroenterol. Hepatol. 20(6), 506-511 (2008
142. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: An open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am. J. Gastroenterol. 107(7), 1043-1050 (2012
143. McGee RG, Bakens A, Wiley K, Riordan SM, Webster AC. Probiotics for patients with hepatic encephalopathy. Cochrane Database Syst. Rev. (11), CD008716 (2011
144. Bosoi CR, Parent-Robitaille C, Anderson K, Tremblay M, Rose CF. AST-120 (spherical carbon adsorbent) lowers ammonia levels and attenuates brain edema in bile duct-ligated rats. Hepatology 53(6), 1995-2002 (2011
145. Hiraishi M. The effect of oral adsorbent on surgically induced hepatic failure. Jpn. J. Surg. 17(6), 517-527 (1987
146. Pockros P, Hassanein T, Vierling J et al. phase 2, multicenter, randomized study of ast-120 (spherical carbon adsorbent) vs. lactulose in the treatment of low-grade hepatic encephalopathy (he). J. Hepatol. 50, S43-S44 (2009
147. Brusilow SW, Valle DL, Batshaw M. New pathways of nitrogen excretion in inborn errors of urea synthesis. Lancet 2(8140), 452-454 (1979
148. Enns GM, Berry SA, Berry GT, Rhead WJ, Brusilow SW, Hamosh A. Survival after treatment with phenylacetate and benzoate for urea-cycle disorders. N. Engl. J. Med. 356(22), 2282-2292 (2007
149. Sushma S, Dasarathy S, Tandon RK, Jain S, Gupta S, Bhist MS. Sodium benzoate in the treatment of acute hepatic encephalopathy: A double-blind randomized trial. Hepatology 16(1), 138-144 (1992
150. Efrati C, Masini A, Merli M, Valeriano V, Riggio O. Effect of sodium benzoate on blood ammonia response to oral glutamine challenge in cirrhotic patients: A note of caution. Am. J. Gastroenterol. 95(12), 3574-3578 (2000
151. Mendenhall CL, Rouster S, Marshall L, Weesner R. A new therapy for portal systemic encephalopathy. Am. J. Gastroenterol. 81(7), 540-543 (1986
152. Uribe M, Bosques F, Poo J et al. A double blind randomized trial of sodium benzoate versus lactulose in patients with chronic portal systemic encephalopathy. [Abstract]. Hepatology 8(5), 1449 (1988
153. McGuire BM, Zupanets IA, Lowe ME et al. Pharmacology and safety of glycerol phenylbutyrate in healthy adults and adults with cirrhosis. Hepatology 51(6), 2077-2085 (2010
154. Ghabril M, Zupanets IA, Vierling J et al. Glycerol phenylbutyrate in patients with cirrhosis and episodic hepatic encephalopathy: A pilot study of safety and effect on venous ammonia concentration. Clin. Pharmacol. Drug Dev. 2(3), 278-284 (2013
155. Bak LK, Waagepetersen HS, Sorensen M et al. Role of branched chain amino acids in cerebral ammonia homeostasis related to hepatic encephalopathy. Metab. Brain Dis. 28(2), 209-215 (2013
156. Als-Nielsen B, Koretz RL, Gluud LL, Gluud C. Branched-chain amino acids for hepatic encephalopathy. Cochrane Database Syst. Rev. (2), CD001939 (2004
157. Gluud LL, Dam G, Borre M et al. Oral branched-chain amino acids have a beneficial effect on manifestations of hepatic encephalopathy in a systematic review with meta-Analyses of randomized controlled trials. J. Nutr. 143(8), 1263-1268 (2013
158. Jalan R, Wright G, Davies NA, Hodges SJ. L-Ornithine phenylacetate (OP): A novel treatment for hyperammonemia and hepatic encephalopathy. Med. Hypotheses 69(5), 1064-1069 (2007
159. Ytrebo LM, Kristiansen RG, Maehre H et al. L-ornithine phenylacetate attenuates increased arterial and extracellular brain ammonia and prevents intracranial hypertension in pigs with acute liver failure. Hepatology 50(1), 165-174 (2009
160. Ventura-Cots M, Arranz JA, Simon-Talero M et al. Safety of ornithine phenylacetate in cirrhotic decompensated patients: An open-label, dose-escalating, single-cohort study. J. Clin. Gastroenterol. 47(10), 881-887 (2013
161. Lheureux PE, Penaloza A, Zahir S, Gris M. Science review: Carnitine in the treatment of valproic acid-induced toxicity-what is the evidence? Crit. Care 9(5), 431-440 (2005
162. Limketkai BN, Zucker SD. Hyperammonemic encephalopathy caused by carnitine deficiency. J. Gen. Intern. Med. 23(2), 210-213 (2008
163. Ling P, Lee DJ, Yoshida EM, Sirrs S. Carnitine deficiency presenting with encephalopathy and hyperammonemia in a patient receiving chronic enteral tube feeding: A case report. J. Med. case Rep. 6(1), 227 (2012
164. Karakoc E, Erdem S, Sokmensuer C, Kansu T. Encephalopathy due to carnitine deficiency in an adult patient with gluten enteropathy. Clin. Neurol. Neurosurg. 108(8), 794-797 (2006
165. McKinney AM, Sarikaya B, Spanbauer J, Lohman BD, Uhlmann E. Acute hepatic (or hyperammonemic) encephalopathy: Diffuse cortical injury and the significance of ammonia. AJNR 32(7), E142, author reply E143 (2011
166. Therrien G, Rose C, Butterworth J, Butterworth RF. Protective effect of L-carnitine in ammonia-precipitated encephalopathy in the portacaval shunted rat. Hepatology 25(3), 551-556 (1997
167. Malaguarnera M, Gargante MP, Cristaldi E et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig. Dis. Sci. 53(11), 3018-3025 (2008
168. Malaguarnera M, Bella R, Vacante M et al. Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand. J. Gastroenterol. 46(6), 750-759 (2011
169. Malaguarnera M, Vacante M, Giordano M et al. Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: A randomized, double-blind, placebo-controlled study. Am. J. Clin. Nutr. 93(4), 799-808 (2011
170. Malaguarnera M, Pistone G, Astuto M et al. Effects of L-Acetylcarnitine on cirrhotic patients with hepatic coma: Randomized double-blind, placebo-controlled trial. Dig. Dis. Sci. 51(12), 2242-2247 (2006
171. Malaguarnera M, Risino C, Cammalleri L et al. Branched chain amino acids supplemented with L-Acetylcarnitine versus BCAA treatment in hepatic coma: A randomized and controlled double blind study. Eur. J. Gastroenterol. Hepatol. 21(7), 762-770 (2009
172. Malaguarnera M, Vacante M, Motta M et al. Acetyl-L-carnitine improves cognitive functions in severe hepatic encephalopathy: A randomized and controlled clinical trial. Metab. Brain Dis. 26(4), 281-289 (2011
173. Quinlan GJ, Martin GS, Evans TW. Albumin: Biochemical properties and therapeutic potential. Hepatology 41(6), 1211-1219 (2005
174. Jalan R, Kapoor D. Reversal of diuretic-induced hepatic encephalopathy with infusion of albumin but not colloid. Clin. Sci. 106(5), 467-474 (2004
175. Hassanein TI, Tofteng F, Brown RS Jr. et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 46(6), 1853-1862 (2007
176. Kjaergard LL, Liu J, Als-Nielsen B, Gluud C. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: A systematic review. JAMA 289(2), 217-222 (2003
177. Nakanishi T, Suzuki N, Kuragano T, Nagasawa Y, Hasuike Y. Current topics in therapeutic plasmapheresis. Clin. Exp. Nephrol. 1-9 (2013
178. Stenbøg P, Busk T, Larsen F. Efficacy of liver assisting in patients with hepatic encephalopathy with special focus on plasma exchange. Metab. Brain Dis. 28(2), 333-335 (2013
179. Stirling DP, Koochesfahani KM, Steeves JD, Tetzlaff W. Minocycline as a neuroprotective agent. Neuroscientist 11(4), 308-322 (2005
180. Jiang W, Desjardins P, Butterworth RF. Minocycline attenuates oxidative/nitrosative stress and cerebral complications of acute liver failure in rats. Neurochem. Int. 55(7), 601-605 (2009
181. Maddrey WC. Drug-induced hepatotoxicity: 2005. J. Clin. Gastroenterol. 39(4 Suppl. 2), S83-S89 (2005
182. Als-Nielsen B, Gluud LL, Gluud C. Benzodiazepine receptor antagonists for hepatic encephalopathy. Cochrane Database Syst. Rev. (2), CD002798 (2004
183. Bassett ML, Mullen KD, Skolnick P, Jones EA. Amelioration of hepatic encephalopathy by pharmacologic antagonism of the GABAA-benzodiazepine receptor complex in a rabbit model of fulminant hepatic failure. Gastroenterology 93(5), 1069-1077 (1987
184. Arafa MH, Atteia HH. Sildenafil citrate attenuates the deleterious effects of elevated ammonia. Toxicol. Mech. Methods 23(6), 402-411 (2013